KMDA vs MCK vs GRFS Stock Comparison

Kamada, Mckesson and Grifols Prices as of Oct 26, 2026 Peers: Industry group
KMDA Kamada Ltd
$7.94 -8.9% 1M +15.6% 1Y
Market cap
$464.05M
P/E
21.0x
Revenue (TTM)
$191.85M
Div. yield
0.06%
Biotechnology Healthcare
5 wins
MCK Mckesson Corp
$992.64 +14.5% 1M +23.8% 1Y
Market cap
$116.75B
P/E
25.4x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
5 wins
GRFS Grifols SA
$7.92 +7.8% 1M -16.3% 1Y
Market cap
$5.39B
P/E
11.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

12 decided of 12

Mckesson leads on 5 of the 12 questions below (Mckesson 5, Kamada 5, Grifols 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionKMDAMCKGRFSLeader
Larger companyMarket capitalisation $464.05M $116.75B $5.39B MCK
Cheaper on earningsLower P/E, profitable companies only 21.0x 25.4x 11.9x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.9x 21.1x 8.5x GRFS
Faster revenue growthRevenue growth, trailing twelve months +13.2% +8.8% — KMDA
More profitableNet margin, trailing twelve months 11.5% 1.1% — KMDA
Better return on capitalReturn on invested capital 10.2% 107.9% — MCK
Less leveragedLower net debt / EBITDA -1.5x 0.6x — KMDA
Higher dividend yieldTrailing dividend yield 0.06% 0.00% 0.00% KMDA
Better 1-year returnPrice return, last 12 months +15.6% +23.8% -16.3% MCK
Better 5-year returnAnnualised price return, 5 years +6.9%/yr +37.4%/yr -9.9%/yr MCK
Less volatileAnnualised volatility, 1 year 34.8% 30.7% 32.4% MCK
Higher overall scoreMean of the five percentile scores vs peers 84/100 58/100 57/100 KMDA

Percentile Scorecard

KMDAMCKGRFS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisKMDAMCKGRFS
Valuation 97 #21 of 626 50 #13 of 25 99 #6 of 626
Growth 71 #179 of 604 65 #9 of 24 –
Profitability 87 #73 of 555 65 #9 of 24 –
Financial Health 75 #167 of 658 48 #14 of 26 14 #566 of 658
Shareholder Returns 90 #37 of 368 60 #7 of 16 56 #161 of 368
Overall 84 58 57
  • KMDA ranked among 673 companies in Pharmaceuticals and Biotechnology
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • GRFS ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodKMDAMCKGRFSSPY
1 month -8.9%+14.5%+7.8% -0.8%
3 months +13.6%+16.7%+2.2% +3.5%
6 months -3.2%+19.8%-2.6% +7.0%
Year to date +12.5%+21.0%-15.3% +12.2%
1 year +15.6%+23.8%-16.3% +13.0%
3 years +91.8%+121.6%+1.0% +86.3%
3 years, per year +24.3%+30.4%+0.3% +23.1%
5 years +39.8%+388.9%-40.5% +68.6%
5 years, per year +6.9%+37.4%-9.9% +11.0%
10 years +32.3%+526.0%-46.6% +258.0%
10 years, per year +2.8%+20.1%-6.1% +13.6%

Risk

MeasureKMDAMCKGRFSSPY
Volatility, 1Y 34.8%30.7%32.4% 12.7%
Downside volatility, 1Y 33.2%27.3%34.1% 12.7%
Beta vs S&P 500, 1Y 1.01-0.260.95 1.00
Return / volatility, 1Y 0.450.78-0.50 1.02
Max drawdown, 5Y -44.4%-27.2%-58.9% -25.4%
From 52-week high -14.7%-3.6%-18.5% -1.8%
52-week high $9.31$1,030.18$9.72 $779.14
52-week low $6.62$725.17$7.02 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleKMDAMCKGRFS
P/E now vs peer median 20.7xmedian 17.1x 25.7xmedian 24.3x 11.9xmedian 17.1x
P/S now vs peer median 2.4xmedian 8.8x 0.3xmedian 0.3x 0.6xmedian 8.8x
EV/EBITDA now vs peer median 9.1xmedian 17.1x 16.6xmedian 13.5x —median 17.1x
P/FCF now vs peer median 17.4xmedian 18.0x 18.0xmedian 15.6x 7.6xmedian 18.0x
P/B now vs peer median 1.7xmedian 2.1x -27.3xmedian 2.5x 0.6xmedian 2.1x
PEG now vs peer median 0.29median 0.31 2.15median 1.33 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsKMDAMCKGRFS
Revenue $191.85M $410.98B –
Gross profit $78.31M $14.96B –
Operating income $27.83M $6.50B –
Net income $22.25M $5.30B –
Free cash flow $26.32M $6.42B –
R&D $9.91M – –
EPS (diluted) $0.38 $38.52 –
Cash & equivalents $29.47M $5.16B $969.15M
Total debt $74.86M $9.73B $44.00B
Shares (diluted) 58.35M 119.20M 681.57M
Enterprise value $173.11M $100.65B $1.74B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricKMDAMCKGRFS
P/E 20.7x 25.7x 11.9x
P/FCF 17.4x 18.0x 7.6x
P/Operating cash flow 12.8x 16.9x –
P/S 2.4x 0.3x 0.6x
P/B 1.7x -27.3x 0.6x
P/Tangible book 1.7x -14.0x 0.9x
EV/EBITDA 9.1x 16.6x –
EV/EBIT 14.2x 18.5x –
EV/Revenue 2.1x 0.3x –
EV/FCF 15.0x 18.8x –
EV/Operating cash flow 11.0x 17.6x –
PEG (3Y EPS CAGR) 0.29 2.15 –

Growth

14 metrics
MetricKMDAMCKGRFS
Revenue growth (1Y) 13.2% 8.8% –
Revenue CAGR (3Y) 9.6% 13.1% –
Gross profit growth (1Y) 5.9% 11.2% –
Gross profit CAGR (3Y) 12.9% 6.6% –
Operating income growth (1Y) 10.3% 46.6% –
Operating income CAGR (3Y) 43.1% 13.5% –
Net income growth (1Y) 17.0% 58.1% –
Net income CAGR (3Y) 258.5% 10.7% –
EPS growth (1Y) 14.5% 52.8% –
EPS CAGR (3Y) 70.4% 12.0% –
Operating cash flow growth (1Y) -10.9% 4.7% –
Operating cash flow CAGR (3Y) 5.6% 10.7% –
Free cash flow growth (1Y) -16.7% 6.8% –
Free cash flow CAGR (3Y) 1.0% 11.3% –

Profitability

14 metrics
MetricKMDAMCKGRFS
Gross margin 40.8% 3.6% –
EBITDA margin 22.5% 1.8% –
Operating margin 14.5% 1.6% –
Pretax margin 13.9% 1.6% –
Net margin 11.5% 1.1% –
FCF margin 13.7% 1.6% –
Operating cash flow margin 18.6% 1.7% –
Return on equity 8.4% – –
Return on assets 5.8% 6.2% –
Return on invested capital 10.2% 107.9% –
Return on capital employed 8.3% 43.4% –
Asset turnover 0.5x 4.8x –
Cash conversion (OCF / net income) 1.6x 1.3x –
Stock comp / revenue 1.1% – –

Financial Health

11 metrics
MetricKMDAMCKGRFS
Debt / assets 1.6% 11.0% 48.9%
Debt / equity 0.0x -2.3x 1.3x
Net debt / EBITDA -1.5x 0.6x –
Debt / FCF 0.2x 1.5x –
Liabilities / assets 29.6% 104.8% 61.4%
Equity / assets 70.4% -4.8% 38.6%
Interest coverage 93.7x 23.6x –
Current ratio 4.1x 0.9x 2.5x
Quick ratio 2.3x 0.5x 0.8x
Cash ratio 1.4x 0.1x 0.4x
Altman Z-score 3.56 5.90 –

Shareholder Returns

7 metrics
MetricKMDAMCKGRFS
Dividend yield 5.3% 0.3% 1.4%
Net buyback yield 0.0% 5.7% –
Shareholder yield 5.3% 6.1% 1.4%
Payout ratio (earnings) 129.6% 7.4% –
Payout ratio (FCF) 109.6% 6.1% –
Dividend growth (1Y) – 11.3% –
Dividend CAGR (3Y) – 10.0% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusKMDAMCKGRFS
Forward P/E 15.9xFY2026 21.1xFY2026 8.5xFY2026
EPS, next fiscal year $0.50FY2026 $47.14FY2026 $0.93FY2026
EPS growth, next FY +38.9%FY2026 +20.5%FY2026 +9.4%FY2026
EPS growth, the year after +24.0% +11.1% +26.9%
Revenue, next fiscal year $209.90MFY2026 $444.51BFY2026 $8.89BFY2026
Revenue growth, next FY +16.3%FY2026 +10.2%FY2026 +0.1%FY2026
Revenue growth, the year after +13.6% +1.4% +10.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersKMDAMCKGRFS
Held by institutions 8.6% 89.1% 21.0%
Institutions holding 50 2,007 166
Change in shares held, QoQ -3.1% -0.7% -0.5%
Institutions buying 24 879 73
Institutions selling 18 791 65
Buyers to sellers 1.33 1.11 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

KMDAMCKGRFS
KMDA 1.00 -0.01 0.20
MCK -0.01 1.00 0.01
GRFS 0.20 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, KMDA, MCK and GRFS?

Mckesson (MCK) is the largest by market capitalisation: Kamada (KMDA) $464.05M, Mckesson (MCK) $116.75B, Grifols (GRFS) $5.39B.

Which stock is cheaper, KMDA, MCK and GRFS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Kamada (KMDA) 21.0x, Mckesson (MCK) 25.4x, Grifols (GRFS) 11.9x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Kamada (KMDA) 15.9x, Mckesson (MCK) 21.1x, Grifols (GRFS) 8.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Kamada (KMDA) grew revenue fastest over the trailing twelve months: Kamada (KMDA) +13.2%, Mckesson (MCK) +8.8%.

Which company is more profitable?

Kamada (KMDA) has the highest net margin (Kamada (KMDA) 11.5%, Mckesson (MCK) 1.1%). On return on invested capital, Mckesson (MCK) leads (Kamada (KMDA) 10.2%, Mckesson (MCK) 107.9%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: Kamada (KMDA) +15.6%, Mckesson (MCK) +23.8%, Grifols (GRFS) -16.3%. Over five years, Mckesson (MCK) compounded fastest (Kamada (KMDA) +6.9%/yr, Mckesson (MCK) +37.4%/yr, Grifols (GRFS) -9.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Kamada (KMDA) has the highest dividend yield: Kamada (KMDA) 0.06%, Mckesson (MCK) 0.00%, Grifols (GRFS) 0.00%. Grifols (GRFS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Kamada (KMDA) 34.8%, Mckesson (MCK) 30.7%, Grifols (GRFS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, KMDA, MCK and GRFS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.